Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Company Data

Name ORUKA THERAPEUTICS INC.

Company Oruka Therapeutics, Inc.

Symbol ORKA

Website http://www.orukatx.com

Primary Exchange

Frankfurt

WKN A3DPH3

ISIN US6876041087

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Lawrence Otto Klein

Market Capitalization 496 Mio

Country United States of America

Currency EUR

Employees 0,0 T

Address 221 Crescent Street Building 23, Suite 105, Menlo Park

Dividends from 'ORUKA THERAPEUTICS INC.'

Ex-Date	Dividend per Share
29.08.2024	1,61 USD
26.08.2024	0,00 USD

Stock Splits

Date	Split
03.09.2024	1:12

ID Changes

Date	From	To
03.09.2024	ABIO	ORKA
27.01.2009	NUVO	ABIO

Ticker Symbols

Name	Symbol
Frankfurt	HQ1.F
NASDAQ	ORKA

More Shares

Investors who hold ORUKA THERAPEUTICS INC. also have the following shares in their portfolio:

CITIGROUP INC14/26 MTN Bond

SOUTHERN PACIFIC SECURITIES D PLC 'A' MTG BCKD FRN 10/03/40 £(BR) Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog